The subsidiary of Jinjiang Pharmaceutical Co., Ltd. (600488.SH) - Amikacin Sulfate Injection, passed the consistency evaluation of generic drugs.

News from the Securities Times app, Jin Medicine (600488.SH) announced that recently, its subsidiary Hubei Jin Medicine Pharmaceutical Co., Ltd. has received the "Drug Supplementary Application Approval Notice" for the approval of amikacin sulfate injection issued by the National Medical Products Administration. The drug has been approved through the generic drug quality and efficacy consistency evaluation. This drug is suitable for severe infections caused by sensitive gram-negative bacilli and staphylococcus (methicillin-sensitive strains).